{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:55:19Z","timestamp":1792803319963,"version":"4.5.0"},"reference-count":140,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL173059"],"award-info":[{"award-number":["R01HL173059"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Massachusetts General Brigham","award":["GR0246597"],"award-info":[{"award-number":["GR0246597"]}],"id":[{"id":"https:\/\/ror.org\/04b6nzv94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Chronic Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) represent one of the most treatment-refractory bacterial diseases, sustained by biofilm formation, metabolic dormancy, and adaptive antibiotic resistance evolution. While bacteriophage (phage) therapy has emerged as a promising alternative for multidrug-resistant (MDR) pathogens, clinical studies in CF have demonstrated transient reductions in bacterial burden without achieving complete eradication. This review integrates molecular, evolutionary, and immunological findings to explain the multifactorial barriers that limit phage therapeutic efficacy in chronic CF infections. We highlight three major obstacles: (i) bacterial dormancy and persistence within biofilms that restrict phage adsorption and replication; (ii) hypermutability and extensive genotypic diversification of CF-adapted P. aeruginosa, which accelerate phage resistance evolution and necessitate broad host-range coverage; and (iii) CF-specific immune constraints\u2014including a dysfunctional innate immune system and phage-neutralizing humoral immunity\u2014that reduce phage bioavailability and undermine sustained bacterial clearance. Emerging strategies to overcome these challenges include the discovery of dormant-targeting phages capable of replicating in metabolically quiescent cells, evolution-informed phage training to delay resistance evolution, and synthetic phage engineering approaches designed to disrupt biofilms and expand host-range coverage. In parallel, computational or artificial intelligence (AI)-guided frameworks for phage cocktail design and cystic fibrosis transmembrane conductance regulator (CFTR) modulator-mediated restoration of host immune function together offer a more integrated therapeutic paradigm that unites phage biology and host immune context. By unifying clinical outcomes with mechanistic, evolutionary, and immunological perspectives, this review outlines a next-generation framework for phage therapy in CF aimed at achieving more durable therapeutic outcomes.<\/jats:p>","DOI":"10.3390\/antibiotics15020125","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:27:11Z","timestamp":1769509631000},"page":"125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phage-Based Approaches to Chronic Pseudomonas aeruginosa Lung Infection in Cystic Fibrosis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8026-9495","authenticated-orcid":false,"given":"Wontae","family":"Hwang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-8617","authenticated-orcid":false,"given":"Ji Hyun","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-9392","authenticated-orcid":false,"given":"Bryan R.","family":"Lenneman","sequence":"additional","affiliation":[{"name":"Mucosal Immunology and Biology Research Center, Division of Pediatric Gastroenterology and Nutrition, Massachusetts General Brigham, Boston, MA 02129, USA"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lael M.","family":"Yonker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Almughem, F.A., Aldossary, A.M., Tawfik, E.A., Alomary, M.N., Alharbi, W.S., Alshahrani, M.Y., and Alshehri, A.A. (2020). Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070616"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00408-024-00733-y","article-title":"Pseudomonas aeruginosa Infection and Inflammation in Cystic Fibrosis: A Pilot Study with Lung Explants and a Novel Histopathology Scoring System","volume":"202","author":"Malhotra","year":"2024","journal-title":"Lung"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Acosta, N., Waddell, B., Heirali, A., Somayaji, R., Surette, M.G., Workentine, M.L., Rabin, H.R., and Parkins, M.D. (2020). Cystic Fibrosis Patients Infected with Epidemic Pseudomonas aeruginosa Strains Have Unique Microbial Communities. Front. Cell Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00173"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Manos, J. (2021). Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections. Microorganisms, 9.","DOI":"10.3390\/microorganisms9091874"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00284-022-03048-4","article-title":"High Rates of Extensively Drug-Resistant Pseudomonas aeruginosa in Children with Cystic Fibrosis","volume":"79","year":"2022","journal-title":"Curr. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e0051924","DOI":"10.1128\/mbio.00519-24","article-title":"Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis","volume":"15","author":"Armbruster","year":"2024","journal-title":"mBio"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hynes, J., Taggart, C.C., Tirouvanziam, R., and Coppinger, J.A. (2025). Innate Immunity in Cystic Fibrosis: Varied Effects of CFTR Modulator Therapy on Cell-to-Cell Communication. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062636"},{"key":"ref_11","unstructured":"Cystic Fibrosis Foundation (2025, December 01). 2024 Patient Registry Highlights. Available online: https:\/\/www.cff.org\/medical-professionals\/2024-patient-registry-highlights."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e187996","DOI":"10.1172\/JCI187996","article-title":"Bacteriophage therapy for multidrug-resistant infections: Current technologies and therapeutic approaches","volume":"135","author":"Kim","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1038\/s41467-025-60598-4","article-title":"Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: A randomized first-in-human trial","volume":"16","author":"Weiner","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: A multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_15","unstructured":"(2025, December 01). SESSION 4: Clinical Use of Bacteriophage Therapeutics, Available online: https:\/\/www.fda.gov\/media\/159400\/download."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Niazi, S.K. (2025). Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081115"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1038\/s41467-025-64608-3","article-title":"Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance","volume":"16","author":"Moon","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fukaya-Shiba, A., Ogata, A., Kuribayashi, R., Sakurai, A., Suzuki, K., Takadama, S., Nishimura, J., Uchiyama, J., Ohge, H., and Takeuchi, T. (2025). Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1713471"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e0207121","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the Use of Phage Therapy in Clinical Practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"ref_21","unstructured":"(2025). Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients with Chronic Pseudomonas Aeruginosa Pulmonary Infection. Standard No. Identifier: NCT05010577. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05010577."},{"key":"ref_22","unstructured":"(2025, December 01). Safety Concerns Halt BX004 Phage Therapy Trial for CF Infection. Available online: https:\/\/cysticfibrosisnewstoday.com\/news\/safety-concerns-halt-bx004-phage-therapy-trial-cf-infection\/?preview_id=98562."},{"key":"ref_23","unstructured":"(2024). Ph 1\/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects with Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis (SWARM-Pa). Standard No. Identifier: NCT04596319. Available online: https:\/\/clinicaltrials.gov\/study\/NCT04596319."},{"key":"ref_24","unstructured":"(2025, December 01). Phage Cocktail, AP-PA02, Safely Lowers P. Aeruginosa Load in CF Trial. Available online: https:\/\/cysticfibrosisnewstoday.com\/news\/ap-pa02-safely-treat-pseudomonas-aeruginosa-infection\/."},{"key":"ref_25","unstructured":"(2025, December 01). Pseudomonas aeruginosa Phage Product Candidates. Available online: https:\/\/www.armatapharma.com\/pipeline\/ap-pa02\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1186\/s13063-022-07047-5","article-title":"Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: Study protocol for a phase 1b\/2, multicenter, randomized, double-blind, placebo-controlled trial","volume":"23","author":"Tamma","year":"2022","journal-title":"Trials"},{"key":"ref_27","unstructured":"(2025). A Phase 1b\/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized with Pseudomonas Aeruginosa. Standard No. Identifier: NCT05453578. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05453578."},{"key":"ref_28","unstructured":"(2025). Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection (Tailwind). Standard No. Identifier: NCT05616221. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05616221."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.healun.2018.01.376","article-title":"Bacteriophage Treatment in a Lung Transplant Recipient","volume":"37","author":"Aslam","year":"2018","journal-title":"J. Heart Lung Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jpids\/pix056","article-title":"Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy","volume":"7","author":"Duplessis","year":"2018","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13054-017-1709-y","article-title":"Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury\u2014A case report","volume":"21","author":"Jennes","year":"2017","journal-title":"Crit. Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.medj.2023.07.002","article-title":"Refractory Pseudomonas aeruginosa infections treated with phage PASA16: A compassionate use case series","volume":"4","author":"Onallah","year":"2023","journal-title":"Med"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dky263","article-title":"Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages","volume":"73","author":"Ferry","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Eiferman, V., Vion, P.A., and Bleibtreu, A. (2025). Phage Therapy as a Rescue Treatment for Recurrent Pseudomonas aeruginosa Bentall Infection. Viruses, 17.","DOI":"10.3390\/v17010123"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Blasco, L., Lopez-Hernandez, I., Rodriguez-Fernandez, M., Perez-Florido, J., Casimiro-Soriguer, C.S., Djebara, S., Merabishvili, M., Pirnay, J.P., Rodriguez-Bano, J., and Tomas, M. (2023). Case report: Analysis of phage therapy failure in a patient with a Pseudomonas aeruginosa prosthetic vascular graft infection. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1199657"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/s41467-023-39370-z","article-title":"Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa","volume":"14","author":"Kohler","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2300355","DOI":"10.1002\/adtp.202300355","article-title":"Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy","volume":"7","author":"Kang","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e0070223","DOI":"10.1128\/msphere.00702-23","article-title":"Liver sinusoidal cells eliminate blood-borne phage K1F","volume":"9","author":"McCourt","year":"2024","journal-title":"mSphere"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e181309","DOI":"10.1172\/jci.insight.181309","article-title":"The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo","volume":"9","author":"Echterhof","year":"2024","journal-title":"JCI Insight"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100440","DOI":"10.1016\/j.opresp.2025.100440","article-title":"Phage Therapy for Respiratory Tract Infections","volume":"6","year":"2024","journal-title":"Open Respir. Arch."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kazmierczak, Z., Majewska, J., Miernikiewicz, P., Miedzybrodzki, R., Nowak, S., Harhala, M., Lecion, D., Keska, W., Owczarek, B., and Ciekot, J. (2021). Immune Response to Therapeutic Staphylococcal Bacteriophages in Mammals: Kinetics of Induction, Immunogenic Structural Proteins, Natural and Induced Antibodies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.639570"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s13337-021-00673-8","article-title":"Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model","volume":"32","author":"Archana","year":"2021","journal-title":"Virusdisease"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14802","DOI":"10.1038\/srep14802","article-title":"Mammalian Host-Versus-Phage immune response determines phage fate in vivo","volume":"5","author":"Miernikiewicz","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00408-024-00700-7","article-title":"Phage Therapy for Respiratory Infections: Opportunities and Challenges","volume":"202","author":"Khosravi","year":"2024","journal-title":"Lung"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jconrel.2022.05.021","article-title":"Paving the way for phage therapy using novel drug delivery approaches","volume":"347","author":"Briot","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/med.21572","article-title":"Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review","volume":"39","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jgar.2021.11.009","article-title":"Isolation of persister cells within the biofilm and relative gene expression analysis of type II toxin\/antitoxin system in Pseudomonas aeruginosa isolates in exponential and stationary phases","volume":"28","author":"Zadeh","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1126\/science.1099390","article-title":"Bacterial persistence as a phenotypic switch","volume":"305","author":"Balaban","year":"2004","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Soares, A., Alexandre, K., and Etienne, M. (2020). Tolerance and Persistence of Pseudomonas aeruginosa in Biofilms Exposed to Antibiotics: Molecular Mechanisms, Antibiotic Strategies and Therapeutic Perspectives. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.02057"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1126\/science.1211037","article-title":"Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria","volume":"334","author":"Nguyen","year":"2011","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1128\/JB.01651-09","article-title":"Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis","volume":"192","author":"Mulcahy","year":"2010","journal-title":"J. Bacteriol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bartell, J.A., Cameron, D.R., Mojsoska, B., Haagensen, J.A.J., Pressler, T., Sommer, L.M., Lewis, K., Molin, S., and Johansen, H.K. (2020). Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1009112"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41467-023-44157-3","article-title":"Phage Paride can kill dormant, antibiotic-tolerant cells of Pseudomonas aeruginosa by direct lytic replication","volume":"15","author":"Maffei","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s43705-023-00299-5","article-title":"Slow growing bacteria survive bacteriophage in isolation","volume":"3","author":"Attrill","year":"2023","journal-title":"ISME Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4161\/bioe.32110","article-title":"Transcription regulation mechanisms of bacteriophages: Recent advances and future prospects","volume":"5","author":"Yang","year":"2014","journal-title":"Bioengineered"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1574-6976.2006.00015.x","article-title":"Bacteriophage replication modules","volume":"30","author":"Weigel","year":"2006","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2513377122","DOI":"10.1073\/pnas.2513377122","article-title":"Quantifying phage infectivity from characteristics of bacterial population dynamics","volume":"122","author":"Blazanin","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e14543","DOI":"10.1111\/1751-7915.14543","article-title":"Phages produce persisters","volume":"17","author":"Kirigo","year":"2024","journal-title":"Microb. Biotechnol."},{"key":"ref_59","first-page":"RP107825","article-title":"Viral commitment to infection depends on host metabolism","volume":"14","author":"Marantos","year":"2025","journal-title":"eLife"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s44259-025-00158-4","article-title":"Lipopolysaccharide clustering in colistin persistent and resistant bacteria","volume":"3","author":"Wang","year":"2025","journal-title":"NPJ Antimicrob. Resist."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e00877-19","DOI":"10.1128\/msystems.00877-19","article-title":"Biofilm Structure Promotes Coexistence of Phage-Resistant and Phage-Susceptible Bacteria","volume":"5","author":"Simmons","year":"2020","journal-title":"mSystems"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ismej.2017.190","article-title":"Phage mobility is a core determinant of phage\u2013bacteria coexistence in biofilms","volume":"12","author":"Simmons","year":"2018","journal-title":"ISME J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10219","DOI":"10.1038\/s41467-025-65014-5","article-title":"Directed evolution of phages in biofilms enhances Pseudomonas aeruginosa control through improved lipopolysaccharide recognition","volume":"16","author":"Meneses","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"wraf065","DOI":"10.1093\/ismejo\/wraf065","article-title":"Phage\u2013phage competition and biofilms affect interactions between two virulent bacteriophages and Pseudomonas aeruginosa","volume":"19","author":"Korf","year":"2025","journal-title":"ISME J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41392-024-01866-5","article-title":"Bacterial persisters: Molecular mechanisms and therapeutic development","volume":"9","author":"Niu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-022-00692-2","article-title":"Gradients and consequences of heterogeneity in biofilms","volume":"20","author":"Jo","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41396-019-0344-9","article-title":"Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates","volume":"13","author":"Windels","year":"2019","journal-title":"ISME J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41467-024-55206-w","article-title":"Mutational signature analysis predicts bacterial hypermutation and multidrug resistance","volume":"16","author":"Hall","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1099\/mic.0.033993-0","article-title":"Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: Strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and\/or lasR mutants","volume":"156","author":"Ciofu","year":"2010","journal-title":"Microbiology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1126\/science.288.5469.1251","article-title":"High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"288","author":"Oliver","year":"2000","journal-title":"Science"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e0048423","DOI":"10.1128\/msystems.00484-23","article-title":"Phenotypes of a Pseudomonas aeruginosa hypermutator lineage that emerged during prolonged mechanical ventilation in a patient without cystic fibrosis","volume":"9","author":"Nozick","year":"2024","journal-title":"mSystems"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"10932","DOI":"10.1038\/srep10932","article-title":"Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis","volume":"5","author":"Clark","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Workentine, M.L., Sibley, C.D., Glezerson, B., Purighalla, S., Norgaard-Gron, J.C., Parkins, M.D., Rabin, H.R., and Surette, M.G. (2013). Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060225"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hall, K.M., Pursell, Z.F., and Morici, L.A. (2022). The role of the Pseudomonas aeruginosa hypermutator phenotype on the shift from acute to chronic virulence during respiratory infection. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.943346"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chom.2017.06.018","article-title":"Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen","volume":"22","author":"Roach","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2021.01.012","article-title":"Neutrophil dysfunction in cystic fibrosis","volume":"20","author":"Yonker","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood.2021014699","article-title":"Neutrophil dysfunction in the pathogenesis of cystic fibrosis","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1038\/s41467-025-61268-1","article-title":"Macrophage-induced reduction of bacteriophage density limits the efficacy of in vivo pulmonary phage therapy","volume":"16","author":"Zborowsky","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcf.2022.06.001","article-title":"Macrophage PD-1 associates with neutrophilia and reduced bacterial killing in early cystic fibrosis airway disease","volume":"21","author":"Margaroli","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10935","DOI":"10.1038\/s41598-020-67729-5","article-title":"Altered iron metabolism in cystic fibrosis macrophages: The impact of CFTR modulators and implications for Pseudomonas aeruginosa survival","volume":"10","author":"Hazlett","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcf.2016.10.011","article-title":"The impact of impaired macrophage functions in cystic fibrosis disease progression","volume":"16","author":"Leveque","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Simonin-Le Jeune, K., Le Jeune, A., Jouneau, S., Belleguic, C., Roux, P.F., Jaguin, M., Dimanche-Boitre, M.T., Lecureur, V., Leclercq, C., and Desrues, B. (2013). Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075667"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"eadg5128","DOI":"10.1126\/sciadv.adg5128","article-title":"CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages","volume":"9","author":"Gillan","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wellems, D., Hu, Y., Jennings, S., and Wang, G. (2023). Loss of CFTR function in macrophages alters the cell transcriptional program and delays lung resolution of inflammation. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1242381"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/JLB.4RU0620-245R","article-title":"Macrophage dysfunction in cystic fibrosis: Nature or nurture?","volume":"109","author":"Turton","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.medj.2024.05.017","article-title":"Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients","volume":"5","author":"Chan","year":"2024","journal-title":"Med"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ciofu, O., and Tolker-Nielsen, T. (2019). Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents-How P. aeruginosa Can Escape Antibiotics. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00913"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/1462-2920.12155","article-title":"The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin","volume":"15","author":"Tseng","year":"2013","journal-title":"Environ. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gordon, M., and Ramirez, P. (2024). Efficacy and Experience of Bacteriophages in Biofilm-Related Infections. Antibiotics, 13.","DOI":"10.3390\/antibiotics13020125"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.tim.2019.04.006","article-title":"Big Impact of the Tiny: Bacteriophage-Bacteria Interactions in Biofilms","volume":"27","author":"Hansen","year":"2019","journal-title":"Trends Microbiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"9987","DOI":"10.1038\/s41467-024-53994-9","article-title":"A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections","volume":"15","author":"Kim","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e0057823","DOI":"10.1128\/aac.00578-23","article-title":"Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models","volume":"67","author":"Holger","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e01341-17","DOI":"10.1128\/mBio.01341-17","article-title":"Associations among Antibiotic and Phage Resistance Phenotypes in Natural and Clinical Escherichia coli Isolates","volume":"8","author":"Allen","year":"2017","journal-title":"mBio"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mib.2019.03.005","article-title":"Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy","volume":"51","author":"Segall","year":"2019","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.1038\/s41467-024-52595-w","article-title":"Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs","volume":"15","author":"Kunisch","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.clinthera.2020.07.014","article-title":"Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?","volume":"42","author":"Luong","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"16302","DOI":"10.1038\/s41598-017-16411-4","article-title":"The O-specific polysaccharide lyase from the phage LKA1 tailspike reduces Pseudomonas virulence","volume":"7","author":"Olszak","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2672.2009.04469.x","article-title":"Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa","volume":"108","author":"Glonti","year":"2010","journal-title":"J. Appl. Microbiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11262-019-01660-4","article-title":"Identification of a lytic Pseudomonas aeruginosa phage depolymerase and its anti-biofilm effect and bactericidal contribution to serum","volume":"55","author":"Mi","year":"2019","journal-title":"Virus Genes"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"100265","DOI":"10.1016\/j.bioflm.2025.100265","article-title":"Cellulophaga algicola alginate lyase and Pseudomonas aeruginosa Psl glycoside hydrolase inhibit biofilm formation by Pseudomonas aeruginosa CF2843 on three-dimensional aggregates of lung epithelial cells","volume":"9","author":"Pal","year":"2025","journal-title":"Biofilm"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e0185324","DOI":"10.1128\/aem.01853-24","article-title":"Applying a polysaccharide lyase from Stenotrophomonas maltophilia to disrupt alginate exopolysaccharide produced by Pseudomonas aeruginosa clinical isolates","volume":"91","author":"Felton","year":"2025","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e00234-19","DOI":"10.1128\/AAC.00234-19","article-title":"Treatment with the Pseudomonas aeruginosa Glycoside Hydrolase PslG Combats Wound Infection by Improving Antibiotic Efficacy and Host Innate Immune Activity","volume":"63","author":"Pestrak","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e1501632","DOI":"10.1126\/sciadv.1501632","article-title":"Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms","volume":"2","author":"Baker","year":"2016","journal-title":"Sci. Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"102482","DOI":"10.1016\/j.mib.2024.102482","article-title":"Implications of lytic phage infections inducing persistence","volume":"79","author":"Kirigo","year":"2024","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1021\/acsinfecdis.4c00349","article-title":"Eradication of Pseudomonas aeruginosa Persister Cells by Eravacycline","volume":"10","author":"Roy","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1111\/1462-2920.12873","article-title":"Combatting bacterial infections by killing persister cells with mitomycin C","volume":"17","author":"Kwan","year":"2015","journal-title":"Environ. Microbiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41587-023-01759-y","article-title":"Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice","volume":"42","author":"Gencay","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41586-024-07681-w","article-title":"In situ targeted base editing of bacteria in the mouse gut","volume":"632","author":"Brodel","year":"2024","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/nbt.3011","article-title":"Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases","volume":"32","author":"Citorik","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nbt.3043","article-title":"Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials","volume":"32","author":"Bikard","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"109930","DOI":"10.1016\/j.celrep.2021.109930","article-title":"Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome","volume":"37","author":"Lam","year":"2021","journal-title":"Cell Rep."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Vashisth, M., Jaglan, A.B., Yashveer, S., Sharma, P., Bardajatya, P., Virmani, N., Bera, B.C., Vaid, R.K., and Anand, T. (2023). Development and Evaluation of Bacteriophage Cocktail to Eradicate Biofilms Formed by an Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa. Viruses, 15.","DOI":"10.3390\/v15020427"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1126\/science.adk1183","article-title":"Diverse phage communities are maintained stably on a clonal bacterial host","volume":"386","author":"Pyenson","year":"2024","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"van der Steen, B.A., Gralka, M., and Mulla, Y. (2024). Rapid resistance evolution against phage cocktails. bioRxiv.","DOI":"10.1101\/2024.08.27.609872"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e2104592118","DOI":"10.1073\/pnas.2104592118","article-title":"Coevolutionary phage training leads to greater bacterial suppression and delays the evolution of phage resistance","volume":"118","author":"Borin","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.copbio.2020.11.003","article-title":"Enhancing phage therapy through synthetic biology and genome engineering","volume":"68","author":"Lenneman","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2019.09.015","article-title":"Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis","volume":"179","author":"Yehl","year":"2019","journal-title":"Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.celrep.2019.09.062","article-title":"Reprogramming Bacteriophage Host Range through Structure-Guided Design of Chimeric Receptor Binding Proteins","volume":"29","author":"Dunne","year":"2019","journal-title":"Cell Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"eadt6432","DOI":"10.1126\/sciadv.adt6432","article-title":"Engineering bacteriophages through deep mining of metagenomic motifs","volume":"11","author":"Huss","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41598-021-81063-4","article-title":"Predicting bacteriophage hosts based on sequences of annotated receptor-binding proteins","volume":"11","author":"Boeckaerts","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"btaf016","DOI":"10.1093\/bioinformatics\/btaf016","article-title":"PHIStruct: Improving phage-host interaction prediction at low sequence similarity settings using structure-aware protein embeddings","volume":"41","author":"Gonzales","year":"2024","journal-title":"Bioinformatics"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1038\/s41564-024-01832-5","article-title":"Prediction of strain level phage-host interactions across the Escherichia genus using only genomic information","volume":"9","author":"Gaborieau","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Noonan, A.J.C., Moriniere, L., Rivera-L\u00f3pez, E.O., Patel, K., Pena, M., Svab, M., Kazakov, A., Deutschbauer, A., Dudley, E.G., and Mutalik, V.K. (2025). Phylogeny-agnostic strain-level prediction of phage-host interactions from genomes. bioRxiv.","DOI":"10.1101\/2025.11.15.688630"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"bbaf656","DOI":"10.1093\/bib\/bbaf656","article-title":"PBIP: A deep learning framework for predicting phage\u2013bacterium interactions at the strain level","volume":"26","author":"Ma","year":"2025","journal-title":"Brief. Bioinform."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Li, M., Liu, G., Song, W., Li, J., Ma, L., and Xiao, M. (2025). Enhancing Strain-level Phage-Host Prediction through Experimentally Validated Negatives and Feature Optimization Strategies. bioRxiv.","DOI":"10.1101\/2025.05.31.656987"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Doud, M.B., Robertson, J.M., and Strathdee, S.A. (2025). Optimizing phage therapy with artificial intelligence: A perspective. Front. Cell Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1611857"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e2313574121","DOI":"10.1073\/pnas.2313574121","article-title":"Predictive phage therapy for Escherichia coli urinary tract infections: Cocktail selection for therapy based on machine learning models","volume":"121","author":"Keith","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"King, S.H., Driscoll, C.L., Li, D.B., Guo, D., Merchant, A.T., Brixi, G., Wilkinson, M.E., and Hie, B.L. (2025). Generative design of novel bacteriophages with genome language models. bioRxiv.","DOI":"10.1101\/2025.09.12.675911"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Robledo-Avila, F.H., Rascon, R., Montanez-Barragan, A., Loyo-Celis, V., Singh, H., McCoy, K.S., Kopp, B.T., and Partida-Sanchez, S. (2025). CFTR mutation leads to intrinsic dysfunction in neutrophils from people with Cystic Fibrosis. bioRxiv.","DOI":"10.1101\/2025.06.08.656500"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Gogoi, D., Gabillard-Lefort, C., Baird, R., Forde, L., Niu, M., Ahmed, S.W., Gunaratnam, C., Williamson, M., Casey, M., and Reeves, E.P. (2025). CFTR Modulator Therapy Impacts Neutrophil CD39 Expression in Cystic Fibrosis. Am. J. Respir. Cell Mol. Biol.","DOI":"10.1165\/rcmb.2025-0262LE"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2102861","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"61","author":"Zhang","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcf.2025.08.014","article-title":"Neutrophil store-operated Ca2+ entry: A correctable biomarker of cystic fibrosis lung disease progression","volume":"24","author":"Wrennall","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.chom.2025.07.009","article-title":"Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation","volume":"33","author":"Durfey","year":"2025","journal-title":"Cell Host Microbe"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e0141825","DOI":"10.1128\/mbio.01418-25","article-title":"mGem: Immune recognition and clearance of bacteriophages-implications for phage therapy","volume":"16","author":"Le","year":"2025","journal-title":"mBio"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/femsre\/fuaa017","article-title":"Current challenges and future opportunities of phage therapy","volume":"44","author":"Pires","year":"2020","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/EBC20240024","article-title":"Phage-specific antibodies: Are they a hurdle for the success of phage therapy?","volume":"68","author":"Washizaki","year":"2024","journal-title":"Essays Biochem."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Lusiak-Szelachowska, M., Miedzybrodzki, R., Rogoz, P., Weber-Dabrowska, B., Zaczek, M., and Gorski, A. (2022). Do Anti-Phage Antibodies Persist after Phage Therapy? A Preliminary Report. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101358"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.7150\/thno.49781","article-title":"A blood circulation-prolonging peptide anchored biomimetic phage-platelet hybrid nanoparticle system for prolonged blood circulation and optimized anti-bacterial performance","volume":"11","author":"Jin","year":"2021","journal-title":"Theranostics"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1751-7915.2008.00028.x","article-title":"PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response","volume":"1","author":"Kim","year":"2008","journal-title":"Microb. Biotechnol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/2\/125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:39:53Z","timestamp":1769510393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/2\/125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":140,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["antibiotics15020125"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15020125","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}